Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma

Research output: Contribution to journalArticle

Abstract

PURPOSE: Kidney cancer has been increasing 1.7% annually. Renal cell carcinoma is the most common kidney cancer and it can metastasize. Our aim was to analyze patients treated with stereotactic body radiation therapy of renal cell carcinoma metastases. MATERIALS AND METHODS: A total of 58 patients (73 lesions) were treated from 2004 to 2016. Patients were candidates for analysis if a maximum of 3 metastases were diagnosed and the primary tumor was resected. Toxicity was classified according to Common Terminology Criteria for Adverse Events version 3. RESULTS: All patients had renal cell carcinoma, in particular the clear cell type in 82.7%. A total of 39 metastases (53.4%) were located in the lungs and 19 (26%) were in the lymph nodes. Less common were metastases to bone (9.5% of cases), the liver (4.1%) and the adrenal gland (6.8%). Median followup was 16.1 months (range 3.5 to 157.1). The local control rate at 12 and 18 months was 90.2% and 90.2%, respectively. The progression-free survival rate at 12 and 18 months was 46.2% (95% CI 32.2-59) and 35% (95% CI 21.4-48.9), respectively. On univariate and multivariable analyses metachronous and single metastases predicted better progression-free survival. Systemic therapy before stereotactic body radiation therapy predicted improved local control in clear cell cases. CONCLUSIONS: Stereotactic body radiation therapy can be considered a safe approach and it provides effective local control of oligometastatic renal cell carcinoma. However, future prospective studies are necessary to evaluate the impact on survival and quality of life.

Original languageEnglish
Pages (from-to)70-75
Number of pages6
JournalThe Journal of urology
Volume201
Issue number1
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Renal Cell Carcinoma
Radiotherapy
Neoplasm Metastasis
Kidney Neoplasms
Disease-Free Survival
Adrenal Glands
Terminology
Survival Rate
Lymph Nodes
Quality of Life
Prospective Studies
Bone and Bones
Lung
Survival
Liver
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

@article{4e18efb86f104326b5474d9a3d59715c,
title = "Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma",
abstract = "PURPOSE: Kidney cancer has been increasing 1.7{\%} annually. Renal cell carcinoma is the most common kidney cancer and it can metastasize. Our aim was to analyze patients treated with stereotactic body radiation therapy of renal cell carcinoma metastases. MATERIALS AND METHODS: A total of 58 patients (73 lesions) were treated from 2004 to 2016. Patients were candidates for analysis if a maximum of 3 metastases were diagnosed and the primary tumor was resected. Toxicity was classified according to Common Terminology Criteria for Adverse Events version 3. RESULTS: All patients had renal cell carcinoma, in particular the clear cell type in 82.7{\%}. A total of 39 metastases (53.4{\%}) were located in the lungs and 19 (26{\%}) were in the lymph nodes. Less common were metastases to bone (9.5{\%} of cases), the liver (4.1{\%}) and the adrenal gland (6.8{\%}). Median followup was 16.1 months (range 3.5 to 157.1). The local control rate at 12 and 18 months was 90.2{\%} and 90.2{\%}, respectively. The progression-free survival rate at 12 and 18 months was 46.2{\%} (95{\%} CI 32.2-59) and 35{\%} (95{\%} CI 21.4-48.9), respectively. On univariate and multivariable analyses metachronous and single metastases predicted better progression-free survival. Systemic therapy before stereotactic body radiation therapy predicted improved local control in clear cell cases. CONCLUSIONS: Stereotactic body radiation therapy can be considered a safe approach and it provides effective local control of oligometastatic renal cell carcinoma. However, future prospective studies are necessary to evaluate the impact on survival and quality of life.",
author = "Ciro Franzese and Davide Franceschini and {Di Brina}, Lucia and DʼAgostino, {Giuseppe Roberto} and Pierina Navarria and Tiziana Comito and Pietro Mancosu and Stefano Tomatis and Marta Scorsetti",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.juro.2018.08.049",
language = "English",
volume = "201",
pages = "70--75",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma

AU - Franzese, Ciro

AU - Franceschini, Davide

AU - Di Brina, Lucia

AU - DʼAgostino, Giuseppe Roberto

AU - Navarria, Pierina

AU - Comito, Tiziana

AU - Mancosu, Pietro

AU - Tomatis, Stefano

AU - Scorsetti, Marta

PY - 2019/1/1

Y1 - 2019/1/1

N2 - PURPOSE: Kidney cancer has been increasing 1.7% annually. Renal cell carcinoma is the most common kidney cancer and it can metastasize. Our aim was to analyze patients treated with stereotactic body radiation therapy of renal cell carcinoma metastases. MATERIALS AND METHODS: A total of 58 patients (73 lesions) were treated from 2004 to 2016. Patients were candidates for analysis if a maximum of 3 metastases were diagnosed and the primary tumor was resected. Toxicity was classified according to Common Terminology Criteria for Adverse Events version 3. RESULTS: All patients had renal cell carcinoma, in particular the clear cell type in 82.7%. A total of 39 metastases (53.4%) were located in the lungs and 19 (26%) were in the lymph nodes. Less common were metastases to bone (9.5% of cases), the liver (4.1%) and the adrenal gland (6.8%). Median followup was 16.1 months (range 3.5 to 157.1). The local control rate at 12 and 18 months was 90.2% and 90.2%, respectively. The progression-free survival rate at 12 and 18 months was 46.2% (95% CI 32.2-59) and 35% (95% CI 21.4-48.9), respectively. On univariate and multivariable analyses metachronous and single metastases predicted better progression-free survival. Systemic therapy before stereotactic body radiation therapy predicted improved local control in clear cell cases. CONCLUSIONS: Stereotactic body radiation therapy can be considered a safe approach and it provides effective local control of oligometastatic renal cell carcinoma. However, future prospective studies are necessary to evaluate the impact on survival and quality of life.

AB - PURPOSE: Kidney cancer has been increasing 1.7% annually. Renal cell carcinoma is the most common kidney cancer and it can metastasize. Our aim was to analyze patients treated with stereotactic body radiation therapy of renal cell carcinoma metastases. MATERIALS AND METHODS: A total of 58 patients (73 lesions) were treated from 2004 to 2016. Patients were candidates for analysis if a maximum of 3 metastases were diagnosed and the primary tumor was resected. Toxicity was classified according to Common Terminology Criteria for Adverse Events version 3. RESULTS: All patients had renal cell carcinoma, in particular the clear cell type in 82.7%. A total of 39 metastases (53.4%) were located in the lungs and 19 (26%) were in the lymph nodes. Less common were metastases to bone (9.5% of cases), the liver (4.1%) and the adrenal gland (6.8%). Median followup was 16.1 months (range 3.5 to 157.1). The local control rate at 12 and 18 months was 90.2% and 90.2%, respectively. The progression-free survival rate at 12 and 18 months was 46.2% (95% CI 32.2-59) and 35% (95% CI 21.4-48.9), respectively. On univariate and multivariable analyses metachronous and single metastases predicted better progression-free survival. Systemic therapy before stereotactic body radiation therapy predicted improved local control in clear cell cases. CONCLUSIONS: Stereotactic body radiation therapy can be considered a safe approach and it provides effective local control of oligometastatic renal cell carcinoma. However, future prospective studies are necessary to evaluate the impact on survival and quality of life.

UR - http://www.scopus.com/inward/record.url?scp=85058925608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058925608&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2018.08.049

DO - 10.1016/j.juro.2018.08.049

M3 - Article

C2 - 30577391

AN - SCOPUS:85058925608

VL - 201

SP - 70

EP - 75

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -